Zobrazeno 1 - 10
of 253
pro vyhledávání: '"Larry J, Copeland"'
Autor:
Monica D. Levine, David M. O'Malley, Paulina J. Haight, Leigha Senter, Vincent Wagner, Kristin L. Bixel, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Eric M. McLaughlin, Floor J. Backes
Publikováno v:
Gynecologic Oncology Reports, Vol 46, Iss , Pp 101173- (2023)
Objective: To determine the recurrence rate and survival among early-stage epithelial ovarian cancer cases considering homologous recombination deficiency (HRD) status. Methods: Single institution retrospective study of stage I/II EOC patients from 2
Externí odkaz:
https://doaj.org/article/bfd62de4649446d5876e8b0e7bf137d0
Autor:
Rachael N. Piver, Vincent M. Wagner, Monica D. Levine, Floor J. Backes, Laura J. Chambers, David E. Cohn, Larry J. Copeland, Casey M. Cosgrove, Christa I. Nagel, David M. O'Malley, Kristin L. Bixel
Publikováno v:
Gynecologic Oncology Reports, Vol 46, Iss , Pp 101156- (2023)
Objective: Gynecologic cancers are associated with a high risk of venous thromboembolism (VTE). The Khorana score is a validated tool to assess risk of VTE in cancer patients. The purpose of this study is to determine if the Khorana score can be used
Externí odkaz:
https://doaj.org/article/8bbfeabd1daa4b9e845502c906bb652a
Autor:
Glenn P. Boyles, MD, Ashlee M. Weaver, MD, David E. Cohn, MD, Floor J. Backes, MD, Larry J. Copeland, MD, Kristin L. Bixel, MD, Jeffrey M. Fowler, MD, David M. O'Malley, MD, Casey M. Cosgrove, MD
Publikováno v:
AJOG Global Reports, Vol 1, Iss 4, Pp 100022- (2021)
BACKGROUND: There is a paucity of literature regarding the outcomes following vulvar excision for nonmalignant lesions. This is a common procedure among gynecologists and gynecologic oncologists, and a body of evidence is warranted to guide clinical
Externí odkaz:
https://doaj.org/article/f57c139424c749ec9c35a0f3f9c75843
Autor:
Monica D. Levine, David A. Barrington, Caitlin E. Meade, Sydney M. Lammers, Eric M. McLaughlin, Adrian A. Suarez, Floor J. Backes, Larry J. Copeland, David M. O'Malley, Casey M. Cosgrove, David E. Cohn, Christa I. Nagel, Ashley S. Felix, Kristin L. Bixel
Publikováno v:
Gynecologic Oncology. 173:15-21
Publikováno v:
Gynecologic Oncology Reports, Vol 37, Iss , Pp 100797- (2021)
Cervical cancer with co-existing pathologic components of squamous cell carcinoma, basaloid morphology and sarcomatoid carcinoma is rare, with limited reports in the literature. Here we present a patient who underwent a modified radical hysterectomy
Externí odkaz:
https://doaj.org/article/590d94fb31274cbebafb22d7b241d87f
Autor:
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, Kathleen Moore, Ana Oaknin, Ignacio Romero, Sami Diab, Larry J Copeland, Bradley J Monk, Robert L Coleman, Thomas J Herzog, Jonathan Siegel, Linda Kasten, Andreas Schlicker, Anke Schulz, Karl Köchert, Annette O Walter, Barrett H Childs, Cem Elbi, Iurie Bulat
Publikováno v:
Scientia
ObjectivesAnetumab ravtansine is an antibody-drug conjugate consisting of a fully human anti-mesothelin monoclonal antibody conjugated to cytotoxic maytansinoid tubulin inhibitor DM4. Mesothelin is highly expressed in ovarian cancer. This phase Ib st
Autor:
Larry J. Copeland, Mark F. Brady, Robert A. Burger, William H. Rodgers, Helen Q. Huang, David Cella, David M. O'Malley, Daron G. Street, Krishnansu S. Tewari, David P. Bender, Robert T. Morris, William J. Lowery, David S. Miller, Summer B. Dewdney, Nick M. Spirtos, Shashikant B. Lele, Saketh Guntupalli, Frederick R. Ueland, Gretchen E. Glaser, Robert S. Mannel, Philip J. DiSaia
Publikováno v:
Journal of Clinical Oncology. 40:4119-4128
PURPOSE To compare taxane maintenance chemotherapy, paclitaxel (P) and paclitaxel poliglumex (PP), with surveillance (S) in women with ovarian, peritoneal, or fallopian tube (O/PC/FT) cancer who attained clinical complete response after first-line pl
Autor:
John K, Chan, Chunqiao, Tian, Joshua P, Kesterson, Michael T, Richardson, Ken, Lin, Krishnansu S, Tewari, Thomas, Herzog, Daniel S, Kapp, Bradley J, Monk, Yovanni, Casablanca, Parviz, Hanjani, Robert M, Wenham, Joan, Walker, Leah, McNally, Larry J, Copeland, Sharon, Robertson, Samuel, Lentz, Nick M, Spirtos, Jeffery G, Bell
Publikováno v:
Gynecologic Oncology. 167:429-435
To determine the clinical and prognostic significance of CA-125 trends prior to, during, and after chemotherapy in high-risk early-stage epithelial ovarian cancer patients.All patients were enrolled in a phase III randomized trial (GOG 157) following
Autor:
Benoit You, Christopher Purdy, Larry J. Copeland, Elizabeth M. Swisher, Michael A. Bookman, Gini Fleming, Robert Coleman, Leslie M. Randall, Krishnansu S. Tewari, Bradley J. Monk, Robert S. Mannel, Joan L. Walker, Fabio Cappuccini, David Cohn, Mahvish Muzaffar, David Mutch, Andrea Wahner-Hendrickson, Lainie Martin, Olivier Colomban, Robert A. Burger
Publikováno v:
Journal of Clinical Oncology. 40:3965-3974
PURPOSE In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMinat
Autor:
Courtney J, Riedinger, Jenna M, Patterson, Floor J, Backes, David, O'Malley, Kristin L, Bixel, Larry J, Copeland, David E, Cohn, Paul J, Goodfellow, Casey M, Cosgrove
Publikováno v:
Gynecologic Oncology. 167:174-180
To examine patients with confirmed endometrial cancer recurrence; evaluate patterns, presentation, and mode of diagnosis.A retrospective review of women with endometrial cancer diagnosis between 2014 and 2020. Disease recurrences were evaluated. Medi